The funding is currently paused AFAIK (whether it has resumed in Q4/Q1, we need to wait for their 10-Q). The OWS contract spells out the cost distributions.
See https://
www.hhs.gov/sites/default/files/novavax-covid-19-vaccine-contract.pdf (Page 16)
Basically ~1.1B is for clinical study. Only around ~400M is for manufacturing. So once the funding is unpaused, they will unlock that and I am pretty sure they included that in their projected revenue.
Stan as usual wanted to give a positive sounding answer without actually providing any tangible information when he said "upside". I cannot stand his talks. Always out there to misguide at every opportunity, painting everything in a positive way without actually providing anything.